Navigation Links
Gene signature assesses breast cancer outcomes

A test that looks at the expression of 70 genes linked to breast cancer can accurately assess a patient's risk of recurrence or death, according to an article in the September 6 issue of the Journal of the National Cancer Institute.

In previous research, scientists at the Netherlands Cancer Institute in Amsterdam identified 231 genes associated with patient outcomes in a group of patients 55 years or younger with breast tumors under 5 cm. The 231 genes were reduced to a core group of 70 that make up a genetic signature to predict outcomes in a separate group of patients from the same institution.

To determine whether the 70-gene signature performed better than traditional risk classifiers, scientists from the international consortium TRANSBIG assigned 307 patients to high- and low-risk groups based on scores from the 70-gene signature and on traditional risk assessment with the Adjuvant Online! software. The patients were followed for 13.6 years and assessed for disease recurrence and death.

The authors found that the 70-gene signature was a more accurate predictor of disease outcomes than assessment with the Adjuvant Online! software. Moreover, statistical analysis indicated that most of the prognostic information provided by traditional risk classifiers was included in the gene classifier.

The authors write, "These results indicate that the gene signature adds independent prognostic information to that provided by a risk assessment based solely on clinico-pathologic factors."

In an accompanying editorial, Richard Simon, D.Sc., of the National Cancer Institute in Rockville, Md., discusses the strengths and limitations of the study by Buyse et al. He suggests improvements that might have been made in the study's design, and writes that the research, "Illustrate[s] many desirable features of gene expression profiling studies for optimizing treatment selection for individual patients."

The 70-gene signature will be pros pectively tested in a larger study called MINDACT, a trial coordinated by the European Organization for Research and Treatment of Cancer. This trial will assess whether the 70-gene signature can better identify who can safely be spared adjuvant chemotherapy in 6000 women with node-negative early-stage breast cancer. If validated, the tool could safely spare 1 in 6 women the burden of adjuvant chemotherapy.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Bioelectronic ‘signatures?hold key to DNA mutations
2. Eleven gene signature reliably predicts cancer prognosis
3. Common molecular signature identified in solid tumors
4. Novel molecular signature marks DNA of embryonic stem cells
5. Common molecular signature identified in solid tumors
6. Scientists use gene signatures to match cancer and other diseases with potentially effective drugs
7. Molecular signature protects cells from viruses
8. Molecular signature may identify cisplatin-sensitive breast tumors
9. Beyond the DNA: Chemical signatures reveal genetic switches in the genome
10. UCLA study assesses cost-effectiveness of Hepatitis B drugs
11. Viral DNA sequence a possible trigger for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... June 21, 2017 , ... Beaker, the industry’s pioneer in ... life sciences industry, today announces a strategic partnership with Alcami Corporation, a leading ... of Beaker’s expertise in executive recruitment solutions, providing Alcami with access to the ...
(Date:6/22/2017)... ... June 21, 2017 , ... Building on the success of ... more informative on the very latest developments in radical life extension. RAADfest combines cutting ... festival, and the empowerment of personal development, making it the largest most comprehensive and ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... in designating infertility as a disease, bringing new hope for prospective parents who ... 2017 annual meeting to back the World Health Organization’s designation in hopes of ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell Consulting’s ... biopharma and life sciences industries, continue to be in demand for their insights ... will be speaking on “The State of Information Governance in the Biopharmaceutical Industry” ...
Breaking Biology Technology: